Adlai Nortye Ltd. American Depositary Shares (ANL) Financial Analysis & Valuation | Quarter Chart

Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squam... more
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development o... more

Company facts

Reported company information and share structure.

Company Share structure
Market Cap$835.48MExchangeNASDAQ
SectorHealthcareIndustryBiotechnology
CountryKYCEOYang Lu
IPO Date2023-09-29CAGR—
Employees109Websitewww.adlainortye.com
Div. Yield—Payout Ratio—
Buy Back Yield—Total Yield—
ANL chart loading...

Key metrics

Reported fundamentals and market-derived technical indicators.

Fundamentals Technicals
EV$152.06MP/E-11.32Forward P/E-53.48PEG—
P/S60.73P/B1.67P/CF-6.16P/FCF-20.51
Sales$19.68MSales 1Y203.24%Sales 3Y—Sales 5Y—
EPS$-1.39EPS 1Y-72.32%EPS 3Y—EPS 5Y—
Sales QoQ—EPS QoQ—Sales QoQ Avg107.29%EPS QoQ Avg-32.02%
Gross Margin100%Operating Margin-113.28%Profit Margin-114.48%ROCE-9.99%
ROA-9%ROE-22%Altman Z Score12.96Piotroski Score2
Current Ratio9.55Quick Ratio9.55Cash Ratio5.26Op. CF Ratio-0.3
Debt/Equity0.12Debt/Assets0.11Lt Debt/Equity0.04Lt Debt/Cap.0.03
Intrst Cov.—Inventory Turnover—Asset Turnover0.08Receivables Turnover74.55
Enterprise Value$152.06MP/E Ratio-11.32
Forward P/E-53.48PEG Ratio—
P/S Ratio60.73P/B Ratio1.67
P/CF Ratio-6.16P/FCF Ratio-20.51
EPS$-1.39EPS Growth 1Y-72.32%
EPS Growth 3Y—EPS Growth 5Y—
Revenue Growth 1Y203.24%Gross Margin100%
Operating Margin-113.28%Profit Margin-114.48%
ROE-22%ROA-9%
ROCE-9.99%Current Ratio9.55
Quick Ratio9.55Cash Ratio5.26
Debt/Equity0.12Interest Coverage—
Altman Z Score12.96Piotroski Score2

View Adlai Nortye Ltd. American Depositary Shares financial charts →

Adlai Nortye Ltd. American Depositary Shares (ANL) valuation & financials

Adlai Nortye Ltd. American Depositary Shares (ANL) has a market capitalization of $835.48M and trades at a price-to-earnings ratio of -11.3. It operates in the Healthcare sector (Biotechnology).

Adlai Nortye Ltd. American Depositary Shares's revenue grew +203.2% over the last year.

Adlai Nortye Ltd. American Depositary Shares's next earnings report is scheduled for March 3, 2027 (provider scheduled date); analysts estimate EPS of $-0.13. Check the earnings calendar to see all companies reporting this week.

📈 Analysts estimate ANL EPS of $-0.13 for the upcoming quarter. See Adlai Nortye Ltd. American Depositary Shares revenue & EPS analyst forecasts for the next four quarters with Quarter Chart Premium.

Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)

Adlai Nortye Ltd. American Depositary Shares revenue & earnings charts →